Shionogi completes acquisition of all rights to Radicava (edaravone)
Shionogi & Co., Ltd. announced that they have completed the transfer of all rights for Radicava (edaravone), including intellectual property rights and sales rights, in major countries and regions to their company from Tanabe Pharma Corporation. Transfer of rights in additional countries and regions is forthcoming. The acquisition and integration of Radicava team members, programs and platforms adds to ongoing strategic investments in rare disease and establishes Shionogi as a commercially viable rare disease company ready to introduce new treatments to patients with unmet medical needs.
Radicava is approved by the FDA and other regulatory authorities around the world for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease for which there is no cure and limited treatment options. Radicava ORS, along with a previously available intravenous formulation, have been used to treat more than 22,000 people with ALS in the U.S. to date.
“By completing the acquisition of RADICAVA we are demonstrating progress toward our 2030 Vision and fulfilling our commitment to supply the best possible medicines to protect the health and wellbeing of the patients we serve,” said Dr. Isao Teshirogi, CEO of Shionogi. “With RADICAVA we are not only acquiring a medication, we are also acquiring an established rare disease capability and assuming responsibility for a relationship with the ALS community. We take this responsibility seriously and commit to providing continuity of care and continued innovation in ALS and rare disease.”
Under the terms of the agreement originally announced on December 22, 2025, Shionogi paid a lump sum of USD 2.5 billion through Shionogi Inc. to acquire the global rights to Radicava and may pay additional royalties on future sales subject to certain conditions. The transaction is expected to be immediately accretive in fiscal year 2026, adding approximately USD $700 million in annual global sales.
“RADICAVA is an important option for people with ALS and we are committed to serving the community’s needs today and working toward future innovations in care,” said Nathan McCutcheon, President and CEO of Shionogi Inc. “We are excited to continue growing our rare disease capabilities with the addition of the talented cross-functional team from Tanabe. The RADICAVA team will complement our efforts to establish a best-in-class rare disease franchise in the U.S. and ensure readiness to deliver future innovations to patients.”
